眼科

• 论著 • 上一篇    下一篇

ENOX2蛋白作为眼眶肿瘤诊断分子标记物的应用研究

张敬学 武珅 闫雪静 刘谦 马建民   

  1. 首都医科大学附属北京同仁医院 北京同仁眼科中心 北京市眼科研究所 眼科学与视觉科学北京市重点实验室 100005
  • 收稿日期:2020-08-07 出版日期:2020-09-25 发布日期:2020-09-25
  • 通讯作者: 马建民,Email: jmma@ sina.com
  • 基金资助:
    北京市属医学科研院所公益发展改革试点项目(京医研2018-2);北京市医院管理中心“登峰”计划(DFL20190201);北京市医院管理中心“青苗”计划(QML20180208)

Application of ENOX2 protein as a diagnostic molecular marker for orbital tumors

Zhang Jingxue, Wu Shen, Yan Xuejing, Liu Qian, Ma Jianmin   

  1. Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Hospital, Capital Medical University, Beijing 100005, China
  • Received:2020-08-07 Online:2020-09-25 Published:2020-09-25
  • Contact: Ma Jianmin, Email: jmma@ sina.com
  • Supported by:
    Beijing Municipal Institute of Public Medical Research Development and Reform Pilot Project (2018-2); Beijing Hospitals Authority Ascent Plan (DFL20190201); Beijing Hospitals Authority Youth Program (QML20180208)

摘要: 目的 探讨烟酰胺腺嘌呤二核苷酸氧化酶二硫键交换蛋白 2(ENOX2)在眼眶肿瘤的血清表达敏感性及组织表达特异性,并探索ENOX2蛋白的表达特征与眼部肿瘤类型的关联。设计 前瞻性病例系列。研究对象 2015 年 11 月至2016 年4月北京同仁医院眼眶肿物患者43例。方法 入组患者收集血清,行肿物切除以及术后病理检测。双向电泳法检测血清中ENOX2蛋白的表达特征,以病理诊断结果为标准,对ENOX2蛋白检测结果进行准确性评价。主要指标 患者血清ENOX2蛋白检测结果及分子特征。结果 病理诊断结果显示,43例入组患者中有非恶性肿瘤患者27例,恶性肿瘤患者16例(基底细胞癌 1 例、淋巴瘤 3 例、睑板腺癌 6 例、鳞状细胞癌 2 例、视网膜母细胞瘤 3 例、黑色素瘤 1 例)。血清ENOX2蛋白检测结果与病理诊断验证后发现,ENOX2蛋白在眼部恶性肿瘤的检出阳性率为94%(基底细胞癌为1/1,100%;淋巴瘤 3/3,100%;睑板腺癌6/6,100%;鳞状细胞癌2/2,100%;视网膜母细胞瘤 2/3,66.70%;黑色素瘤1/1,100%)。并首次发现了睑板腺癌的ENOX2蛋白分子特征(分子量为37 kDa,等电点为4.9)。结论 ENOX2蛋白可以作为眼眶肿瘤早期诊断的潜在血清标志物,并具有一定的肿瘤类型特异性。(眼科, 2020, 29: 401-405)

关键词: 眼眶肿瘤, 分子标志物, 烟酰胺腺嘌呤二核苷酸氧化酶二硫键交换蛋白 2

Abstract: Objective To investigate whether ENOX2 protein can be detected in the serum of patients with orbital tumors, and observe whether the expression of the protein is tissue specificity, and explore the relationship between the expression characteristics of ENOX2 protein and the types of ocular tumors. Design Prospective case series. Participants 43 patients with orbital mass in Beijing Tongren Hospital from November 2015 to April 2016. Methods Serum of enrolled patients was collected. The enrolled patients underwent tumor resection and postoperative pathological examination. The ENOX2 protein detection was carried out using 2D electrophoresis. And the accuracy of ENOX2 protein detection was evaluated based on pathological diagnosis. Main Outcome Measures The detection results and molecular characteristics of ENOX2 protein in patient's serum. Results The final pathological diagnosis showed that there are 27 cases patients of benign tumor, 16 cases of malignant tumor (1 case of basal cell carcinoma, 3 cases of lymphoma, 6 cases of meibomian adenocarcinoma, 2 cases of squamous cell carcinoma, 3 cases of retinoblastoma, 1 case of melanoma). Based on the verification of ENOX2 protein results and pathological diagnosis results, we found and the ENOX2 positive rate of orbital malignancy tumor was 94% (3/3 in limphoma, 100%; 2/2 in squamous cell carcinoma, 100%; 6/6 in meibomian adenocarcinoma, 100%; 2/3 in retinoblastoma, 66.70%). The molecular features of ENOX2 protein in meibomian adenocarcinoma were discovered for the first time (molecular weight is 37 kDa, isoelectric point is 4.9). Conclusion ENOX2 protein can be used as a potential serum marker for the early diagnosis of orbital tumors and has certain specificity. (Ophthalmol CHN, 2020, 29: 401-405)

Key words: orbital tumor, biomarker, nicotinamide adenine dinucleotide oxidase disulfide exchange protein 2